Acrongenomics is currently conducting a clinical comparison study of its Nano-Jeta real time PCR by the detection of Ep-CAM, HER1, HER2, vEGF and beta-actin genes in peripheral blood samples
Currently, molecular diagnostics market needs fast, personalised diagnosis, easy to handle methods, decreased cost and fast therapy decision without compromise in accuracy and reliability.
Once these needs are covered a clear increase in growth rate of molecular diagnostics is expected, says Acrongenomics.
PCR applications in particular will reveal double-digit growth having the biggest share since PCR remains the workhorse for molecular genetic analysis.
Acrongenomics is currently conducting a clinical comparison study of its Nano-Jeta real time PCR against the 'gold standard', the common real time PCR technology, via the detection of Ep-CAM, HER1, HER2, vEGF and beta-actin genes in peripheral blood samples of 500 patients suffering from breast, colon, lung and ovarian cancer.
The objective of the study is to evaluate and compare the Nano-Jeta real time PCR technology against the 'gold standard' real time PCR protocols in regards to stability, sensitivity, specificity, reproducibility and compatibility by using three different types of real time PCR equipment to perform the Nano-Jeta real time PCR application: a) iCycler real-time PCR ; b) Chromo4 real-time PCR; c) light cycler real time PCR.
The study has been designed intentionally to incorporate the most difficult parameters such as blind control, multi-centre with variant and unidentified patient status (primary or metastatic status, follow up or on treatment).
